Cargando…
Definition of a new blood cell count score for early survival prediction for non-small cell lung cancer patients treated with atezolizumab: Integrated analysis of four multicenter clinical trials
IMPORTANCE: Blood cell count test (BCT) is a robust method that provides direct quantification of various types of immune cells to reveal the immune landscape to predict atezolizumab treatment outcomes for clinicians to decide the next phase of treatment. OBJECTIVE: This study aims to define a new B...
Autores principales: | Zhou, Jian-Guo, Wong, Ada Hang-Heng, Wang, Haitao, Jin, Su-Han, Tan, Fangya, Chen, Yu-Zhong, He, Si-Si, Shen, Gang, Frey, Benjamin, Fietkau, Rainer, Hecht, Markus, Carr, Shamus R., Wang, Ruihong, Shen, Bo, Schrump, David S., Ma, Hu, Gaipl, Udo S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9478919/ https://www.ncbi.nlm.nih.gov/pubmed/36119066 http://dx.doi.org/10.3389/fimmu.2022.961926 |
Ejemplares similares
-
Elucidation of the Application of Blood Test Biomarkers to Predict Immune-Related Adverse Events in Atezolizumab-Treated NSCLC Patients Using Machine Learning Methods
por: Zhou, Jian-Guo, et al.
Publicado: (2022) -
Definitive Radiochemotherapie von lokal fortgeschrittenen Kopf-Hals-Tumoren in Kombination mit Immuncheckpointinhibition – neue Konzepte gefragt
por: Hecht, Markus, et al.
Publicado: (2021) -
Immune biological rationales for the design of combined radio- and immunotherapies
por: Hader, Michael, et al.
Publicado: (2020) -
Chemoradiation Increases PD-L1 Expression in Certain Melanoma and Glioblastoma Cells
por: Derer, Anja, et al.
Publicado: (2016) -
Low-Dose Radiotherapy Has No Harmful Effects on Key Cells of Healthy Non-Inflamed Joints
por: Deloch, Lisa, et al.
Publicado: (2018)